Targeting Oncogenic RAS with Tri-Complex RAS(ON) Inhibitors
- RAS(ON) inhibitors selectively target the active GTP-bound form of oncogenic RAS and lead to deep and durable responses in preclinical models of RAS-driven tumors
- RAS(ON) mutant- and multi-selective inhibition has demonstrated anti-tumor activity in RAS addicted PDAC and NSCLC
- Potential combination strategies to forestall/address emerging resistance mechanisms to RAS(ON) inhibition are being explored